Axitinib and Bosutinib in Treating Patients With Chronic, Accelerated, or Blastic Phase Chronic Myeloid Leukemia

Phase 1 Terminated 4 enrolled M.D. Anderson Cancer Center National Cancer Institute (NCI) · collab

Non-randomizedParallel-groupOpen-labelTreatment

Summary

This phase I/II trial studies the side effects and best dose of axitinib and bosutinib and how well they work in treating patients with chronic, accelerated, or blastic phase chronic myeloid leukemia. Axitinib and bosutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

Timeline

Start: 2017-03-20
Primary completion: 2019-11-11
Completion: 2019-11-11

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Axitinib	Small molecule	—	Oral
Subject	Bosutinib	Small molecule	—	Oral

Axitinib and Bosutinib in Treating Patients With Chronic, Accelerated, or Blastic Phase Chronic Myeloid Leukemia

Summary

Timeline

Drugs

Indications